Moderna missed earnings forecasts, posting a net loss of $1.1 billion, or $2.91 per share, 23% below the expectations of analysts polled by Visible Alpha. Revenue was 4% higher than forecasts ...

Shares in Moderna were ticking upwards today after Merck & Co took up an option on a personalised RNA-based cancer vaccine with a payment of $250 million. It is the first time that Merck has ...

The U.S. government has awarded Moderna $590 million to advance the development of its bird flu vaccine, as the country doubles down on efforts to tackle increasing infections in humans.

MSD and partner Moderna have started a late-stage trial of their personalised cancer vaccine V940 as a combination with MSD’s PD-1 inhibitor Keytruda for patients with non-small cell lung cancer ...

Beverly Ortega, a contestant on 'The Bachelor,' had to leave the show due to a severe medical emergency that resulted in a diagnosis of appendicitis. Her sudden departure left fans and fellow ...

In its fourth-quarter earnings report, Moderna’s revenue was down substantially from 2023. Separately, media reports reveal anticipated cuts to the company’s digital team. Moderna continues to ...

After hours: February 14 at 7:59:50 PM EST Loading Chart for MRNA ...